Dolastatin 10 vs Kahalalide F
Head-to-head comparison of Dolastatin 10 (Dolastatin 10) and Kahalalide F (Kahalalide F) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Dolastatin 10 | Kahalalide F |
|---|---|---|
| Category | Experimental | Experimental |
| Full Name | Dolastatin 10 | Kahalalide F |
| Molecular Weight | 771.0 Da | 1111.3 Da |
| Half-Life | N/A | N/A |
| Amino Acids | 5 | N/A |
| Typical Dose | N/A in humans; subnanomolar to low-nanomolar in vitro | 0.1-3 mg/m2 IV in early trials |
| Route | Intravenous | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 300 | 85 |
| Research Status | Pre-clinical | Pre-clinical |
Dolastatin 10 Benefits
- ✓antineoplastic
- ✓microtubule disruption
- ✓antimitotic
- ✓ADC payload scaffold
Kahalalide F Benefits
- ✓antineoplastic
- ✓pro-apoptotic
- ✓membrane-active
- ✓anti-proliferative
Dolastatin 10 Dosing
research-grade in vitro nanomolar use|early IV oncology exploration|no approved dosing regimen
Kahalalide F Dosing
IV infusion in phase I oncology studies|dose escalation used in trials|preclinical nanomolar assays
Dolastatin 10 Side Effects
- ⚠peripheral neuropathy
- ⚠neutropenia
- ⚠fatigue
Kahalalide F Side Effects
- ⚠fatigue
- ⚠nausea
- ⚠transaminase elevation
Research Overview
Dolastatin 10
Dolastatin 10 became famous for extreme cytotoxic potency and its ability to block tubulin polymerization. Although the native compound itself did not become a standard therapy, it inspired a major class of clinically important auristatin-based payloads.
Kahalalide F
Kahalalide F was investigated in multiple preclinical and early clinical cancer studies because of its unusual membrane-disrupting and anti-tumor effects. Development highlighted the promise and limits of marine depsipeptides as oncology leads.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.